KRAS and colonic neoplasm: The FOxTROT (Fluoropyrimidine Oxaliplatin and Targeted Receptor Pre-Operative Therapy) trial was designed to assess whether 6 weeks of an effective combination chemotherapy regimen given preoperatively to patients with radiologically staged, locally advanced, but potentially resectable colon cancer improves disease-free survival, and whether the addition of an EGFR-targeted monoclonal antibody, panitumumab, to preoperative chemotherapy increases tumour shrinkage for patients with wild-type KRAS tumours.